The treatment of secondary hemochromatosis;Therapie der sekundären hämochromatose

Deutsches Arzteblatt

Volumn 106, Issue 30, 2009, Pages 499-504

  Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anemia; Chelators; Hemochromatosis; Myelodysplastic syndrome; Treatment

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

ANEMIA; BLOOD TRANSFUSION; DRUG EFFICACY; DRUG SAFETY; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LIVER FAILURE; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHLEBOTOMY; REVIEW; THALASSEMIA;

CHELATION THERAPY; HEMOCHROMATOSIS; HUMANS; IRON;

EID: 70349297213     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0499     Document Type: Review

References (25)

1. Buja LM, Roberts WC: Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209-221
2. Gattermann N, Porter JB, Lopes LF, Seymour J: Consensus statement on iron overload in myelodysplastic syndromes. Hematology/Oncology Clinics of North America 2005; 19 (Suppl 1): 18-25.
3. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS et al.: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319-324 (Pubitemid 11179024)
4. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T et al.: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299 (Pubitemid 26247987)
5. di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007; 78: 540-542 (Pubitemid 46753589)
6. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603 (Pubitemid 46291823)
7. Leitch H: Improving clinical outcome in patients wtih myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007; 31 (Suppl 3): 7-9.
8. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL: Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632-4639 (Pubitemid 36857840)
9. di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D et al.: Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008; 93: 1385-1388
10. Borgna-Pignatti C, Cohen A: Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130: 86-88 (Pubitemid 27492723)
11. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G: Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95: 2776-2779 (Pubitemid 30235883)
12. Bousquet J, Navarro M, Robert G, Aye P, Michel FB: Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet 1983; 2: 859-860
13. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al.: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573
14. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V et al.: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330. (Pubitemid 34779559)
15. Anderson LJ,Wonke B, Prescott E, Holden S,Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-520 (Pubitemid 35232104)
16. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-1587 (Pubitemid 37022545)
17. Pennell DJ: Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-3744
18. Hoffbrand AV, Cohen A, Hershko O: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24. (Pubitemid 36759630)
19. Tanner MA, Galanello R, Dessi C, Smith GC,Westwood MA, Agus A et al.: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884 (Pubitemid 46598901)
20. Gattermann N, Musch A: Deferasirox. Orale Therapie bei transfusionsbedingter Eisenüberladung. Arzneimitteltherapie 2007; 25: 240-247
21. Cappellini MD, Cohen A, Piga A et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2005; 107: 3455-3462
22. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD et al.: Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 2008; 80: 168-176
23. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462
24. Nathan DG: Oral iron chelation: new drug, old rules. Blood 2008; 111: 483-484
25. Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E: Recent developments in iron chelator therapy. Klin Pädiatr 2007; 219: 158-165 (Pubitemid 46983779)